Search

Your search keyword '"Go, Alan S"' showing total 25 results
Start Over Author "Go, Alan S" Journal american heart journal
25 results on '"Go, Alan S"'

5. Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry

Author

Steinberg, Benjamin A, Blanco, Rosalia G, Ollis, Donna, Kim, Sunghee, Holmes, DaJuanicia N, Kowey, Peter R, Fonarow, Gregg C, Ansell, Jack, Gersh, Bernard, Go, Alan S, Hylek, Elaine, Mahaffey, Kenneth W, Thomas, Laine, Chang, Paul, Peterson, Eric D, Piccini, Jonathan P, and Investigators, ORBIT-AF Steering Committee

Subjects
Clinical Research, Cardiovascular, Patient Safety, Hematology, Heart Disease, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Aged, Anticoagulants, Antithrombins, Atrial Fibrillation, Factor Xa Inhibitors, Humans, Observational Studies as Topic, Outcome Assessment, Health Care, Prospective Studies, Registries, Ventricular Remodeling, ORBIT-AF Steering Committee Investigators, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

BackgroundRecent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC.Methods/designORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to 2 years, including clinical status, outcomes (major adverse cardiovascular events, bleeding), and management of anticoagulation surrounding bleeding events. In addition, detailed data regarding the use of these agents in and around cardiac procedures, their complications, and management of such complications will be collected.ConclusionsThe ORBIT-AF II registry will provide valuable insights into the safety and effectiveness of NOACs used in AF in community practice settings.

Published
2014

6. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

Author

Steinberg, Benjamin A, Kim, Sunghee, Fonarow, Gregg C, Thomas, Laine, Ansell, Jack, Kowey, Peter R, Mahaffey, Kenneth W, Gersh, Bernard J, Hylek, Elaine, Naccarelli, Gerald, Go, Alan S, Reiffel, James, Chang, Paul, Peterson, Eric D, and Piccini, Jonathan P

Subjects
Cardiovascular, Heart Disease, Clinical Research, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Aged, Atrial Fibrillation, Disease Progression, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Incidence, Male, Prognosis, Prospective Studies, Registries, Risk Assessment, Risk Factors, Time Factors, United States, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

BackgroundAtrial fibrillation (AF) is the most common cardiac dysrhythmia and contributes significantly to health care expenditures. We sought to assess the frequency and predictors of hospitalization in patients with AF.MethodsThe ORBIT-AF registry is a prospective, observational study of outpatients with AF enrolled from June 29, 2010, to August 9, 2011. The current analysis included 9,484 participants with 1-year follow-up. Multivariable, logistic regression was used to identify baseline characteristics that were associated with first cause-specific hospitalization.ResultsOverall, 31% of patients with AF studied (n = 2,963) had 1 or more hospitalizations per year and 10% (n = 983) had 2 or more. The most common hospitalization cause was cardiovascular (20 per 100 patient-years vs 3.3 bleeding vs 17 noncardiovascular, nonbleeding). Compared with those not hospitalized, hospitalized patients were more likely to have concomitant heart failure (42% vs 28%, P < .0001), higher mean CHADS2 (1 point for congestive heart failure, hypertension, age ≥75, or diabetes; 2 points for prior stroke or transient ischemic attack) scores (2.5 vs 2.2, P < .0001), and more symptoms (baseline European Heart Rhythm Association class severe symptoms 18% vs 13%, P < .0001). In multivariable analysis, heart failure (adjusted hazard ratio [HR] 1.57 for New York Heart Association III/IV vs none, P < .0001), heart rate at baseline (adjusted HR 1.11 per 10-beats/min increase >66, P < .0001), and AF symptom class (adjusted HR 1.37 for European Heart Rhythm Association severe vs none, P < .0001) were the major predictors of incident hospitalization.ConclusionsHospitalization is common in outpatients with AF and is independently predicted by heart failure and AF symptoms. Improved symptom control, rate control, and comorbid condition management should be evaluated as strategies to reduce health care use in these patients.

Published
2014

13. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)

Author

Ambrosy, Andrew P., primary, Malik, Umar I., additional, Thomas, Rachel C., additional, Parikh, Rishi V., additional, Tan, Thida C., additional, Goh, Choon H., additional, Selby, Van N., additional, Solomon, Matthew D., additional, Avula, Harshith R., additional, Fitzpatrick, Jesse K., additional, Skarbinski, Jacek, additional, Philip, Sephy, additional, Granowitz, Craig, additional, Bhatt, Deepak L., additional, and Go, Alan S., additional

Published
2021
Full Text
View/download PDF

21. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Author

Jackson, Larry R., primary, Kim, Sunghee, additional, Blanco, Rosalia, additional, Thomas, Laine, additional, Ansell, Jack, additional, Fonarow, Gregg C., additional, Gersh, Bernard J., additional, Go, Alan S., additional, Kowey, Peter R., additional, Mahaffey, Kenneth W., additional, Hylek, Elaine M., additional, Peterson, Eric D., additional, and Piccini, Jonathan P., additional

Published
2020
Full Text
View/download PDF

24. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II

Author

Inohara, Taku, primary, Shrader, Peter, additional, Pieper, Karen, additional, Blanco, Rosalia G., additional, Allen, Larry A., additional, Fonarow, Gregg C., additional, Gersh, Bernard J., additional, Go, Alan S., additional, Ezekowitz, Michael D., additional, Kowey, Peter R., additional, Reiffel, James A., additional, Naccarelli, Gerald V., additional, Chan, Paul S., additional, Mahaffey, Kenneth W., additional, Singer, Daniel E., additional, Freeman, James V., additional, Steinberg, Benjamin A., additional, Peterson, Eric D., additional, and Piccini, Jonathan P., additional

Published
2019
Full Text
View/download PDF

25. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry.

Author

Steinberg, Benjamin A, Blanco, Rosalia G, Ollis, Donna, Kim, Sunghee, Holmes, DaJuanicia N, Kowey, Peter R, Fonarow, Gregg C, Ansell, Jack, Gersh, Bernard, Go, Alan S, Hylek, Elaine, Mahaffey, Kenneth W, Thomas, Laine, Chang, Paul, Peterson, Eric D, Piccini, Jonathan P, and ORBIT-AF Steering Committee Investigators

Abstract

Background: Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC.Methods/design: ORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to 2 years, including clinical status, outcomes (major adverse cardiovascular events, bleeding), and management of anticoagulation surrounding bleeding events. In addition, detailed data regarding the use of these agents in and around cardiac procedures, their complications, and management of such complications will be collected.Conclusions: The ORBIT-AF II registry will provide valuable insights into the safety and effectiveness of NOACs used in AF in community practice settings. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results